Stockscreener 앱 받기
42.70
3.13%
-1.38
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Candriam S.C.A. Grows Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
CRNX News Today | Why did Crinetics Pharmaceuticals stock go down today? - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Liquidity Mapping Around (CRNX) Price Events - Stock Traders Daily
Recap Report: Is RSSS affected by consumer sentimentJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
Weekly Recap: Is Crinetics Pharmaceuticals Inc exposed to currency risksPortfolio Performance Report & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March - GlobeNewswire
Recap Report: Is Crinetics Pharmaceuticals Inc exposed to currency risksPortfolio Growth Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals, Inc. (CRNX): Investor Outlook On Its 70% Upside Potential - DirectorsTalk Interviews
Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Stryker (SYK) - The Globe and Mail
Lisanti Capital Growth LLC Purchases New Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Momentum Shift: Can Crinetics Pharmaceuticals Inc. stock outperform in a bear marketWeekly Trend Recap & Safe Entry Trade Reports - baoquankhu1.vn
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - Yahoo Finance
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities By Investing.com - Investing.com Nigeria
Crinetics Pharmaceuticals updates Jeff Knight’s executive title and responsibilities - Investing.com
Why (CRNX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Pullback Watch: Is Crinetics Pharmaceuticals Inc exposed to currency risks2025 Trade Ideas & Community Verified Trade Alerts - baoquankhu1.vn
Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN
Crinetics Pharmaceuticals, Inc. $CRNX Stock Holdings Boosted by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Crinetics Starts Pediatric BALANCE CAH Trial As Valuation Gap Persists - Sahm
Crinetics begins phase 2/3 trial of oral CAH treatment in children - Investing.com Nigeria
Crinetics (CRNX) Launches Phase 2/3 Trial for Atumelnant in Pedi - GuruFocus
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) - The Manila Times
Jim Cramer on Crinetics: “That’s a Better Spec Than Aquestive” - Insider Monkey
Is It Too Late To Consider Crinetics Pharmaceuticals (CRNX) After Strong Multi‑Year Share Gains? - Sahm
Goldman Sachs upgrades Crinetics Pharmaceuticals, Inc. (CRNX) to buy from neutral - MSN
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Goldman Sachs Upgrade And Palsonify Atumelnant Progress - Sahm
Retail Surge: What is the dividend yield of Crinetics Pharmaceuticals Inc2025 Analyst Calls & Fast Gaining Stock Reports - baoquankhu1.vn
Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN
Goldman Sachs Upgrades Crinetics Pharmaceuticals, Inc. (CRNX) To Buy From Neutral - Insider Monkey
Hedge Fund Bets: Can Crinetics Pharmaceuticals Inc be recession proofEarnings Risk Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Why Crinetics Pharmaceuticals (CRNX) Is Up 18.2% After Equity Raise and PALSONIFY, Atumelnant Updates - Sahm
Crinetics Pharmaceuticals discovers new SSTR2 non-peptide-drug conjugates - BioWorld MedTech
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Goldman Sachs Upgrades Crinetics Pharmaceuticals (CRNX) - Nasdaq
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CRNX Upgraded to 'Buy' by Goldman Sachs with New Price Target of $67 | CRNX Stock News - GuruFocus
Crinetics Shares Rise After Goldman Sachs Upgrade - marketscreener.com
The Goldman Sachs Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to Buy - MarketBeat
Crinetics stock rating upgraded by Goldman Sachs on promising CAH drug data - Investing.com Canada
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Equity Raise PALSONIFY Launch And Positive Atumelnant Data - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
How Crinetics Pharmaceuticals Inc. stock trades during market volatility2025 Earnings Surprises & Weekly High Return Stock Opportunities - Улправда
Crinetics Pharmaceuticals Inc. (CRNX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Crinetics Pharmaceuticals prices offering at $45.95 per share - MSN
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Strong Share Price Momentum - Sahm
What risks investors should watch in Crinetics Pharmaceuticals Inc. stockLong Setup & Safe Capital Investment Plans - Улправда
1.12%
0.87%
자본화:
|
볼륨(24시간):